On December 27, 2024, the United States Court of Appeals for the Second Circuit joined other federal circuit courts in adopting ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. The US Court of Appeals for the Federal Circuit (CAFC ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice ...

The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Tecfidera (dimethyl fumarate) is a brand-name oral capsule that’s prescribed for certain types of multiple sclerosis (MS) and clinically isolated syndrome (CIS). Tecfidera has interactions with ...

The lawsuit, filed by whistleblower Steven Camburn, alleges that Novartis illegally remunerated physicians to induce them to prescribe its drug Gilenya, which treats multiple sclerosis ...

More than 3,600 of the signatures submitted for the initiative for the security of medical supplies were invalid. The majority of the problematic signatures, previously validated by the ...

As with other drugs, Azulfidine and Azulfidine EN-tabs (sulfasalazine) can cause side effects, such as headache and nausea and vomiting. If you are not able to tolerate side effects of Azulfidine ...

According to a study commissioned by the Federal Office of Communications (OFCOM), the media literacy of the Swiss population is not very high. Many respondents find it difficult to distinguish ...